ArticleOral and maxillofacial surgery2025
Estimation of salivary myeloid-related protein (calprotectin) level in patients with oral lichen planus: a case-control study.
Article in Oral and maxillofacial surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesOral lichen planus (OLP) is a chronic, autoimmune disease that causes inflammation in the oral mucosa. It has a 1.14% chance of malignant transformation. The pathogenesis of OLP is unclear. Myeloid-related protein (calprotectin) is a protein complex found in various cells and potentially serves as a biomarker for inflammation. We aimed to detect the relationship between salivary calprotectin levels and OLP. MATERIALS AND
methodsThirty patients with OLP and 30 age- and sex-matched healthy controls were recruited from our affiliated Dermatology outpatient clinics. Unstimulated whole saliva was collected (09:00 AM-12:00 PM) under standardized pre-collection restrictions, calprotectin concentration was measured by ELISA, and levels were compared between patients and controls.
resultsPatients with OLP had higher salivary calprotectin levels than controls, with age and disease duration positively correlated. However, we found no significant correlation between salivary calprotectin levels and cutaneous involvement, sex, number of oral sites involved, or types of OLP. The study found substantial differences in calprotectin levels between cases with coexisting nail involvement and those without nail involvement. ROC analysis yielded AUC = 1.00 with an optimal cut-off of > 32 ng/mL (100% sensitivity and 100% specificity).
conclusionHigher salivary calprotectin levels in OLP patients than in healthy subjects suggest that salivary calprotectin may contribute to OLP pathogenesis and can be helpful in disease diagnosis and monitoring. CLINICAL RELEVANCE: The ability to non-invasively measure salivary calprotectin (S100A8/A9) levels makes it an attractive option for diagnostic and monitoring purposes.
Indexed as
Identifiers
41060435What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.